

IVEWSLetter

Vacuum-assisted Excision for Benign Breast Lesions

Hospital Updates:

- · Let's Talk About Levofloxacin
- · New Drugs Available at SPH
- St Paul's Hostpial Antibiogram Microbiology Report

Message from

Managing Director

Time flies in the blink of an eye and the Year of the Horse has come. I'd like to take this opportunity to wish you all a Happy and Prosperous New Year of the Horse!

Chinese New Year has long been one of the most important festivals in our tradition. Not only does it symbolize a year of new hopes, but also a time to show our love, care and blessings to the dearest ones. Yet a question comes up: why the latter seems to be out of our hands most of the time? This story may give you some inspiration and insights.

It begins with a simple question - "What did you miss in your life?" which a woman asked her husband at the age of 25, and in the years after. The first time the husband said he desperately missed a job opportunity; at 35 he said annoyingly that he had just missed a bus; at 45 he regretted missing an opportunity to see his close relative before his death; at 55, he was disappointed to have missed a good chance to retire. He was no longer asked at 75. Looking at his wife lying weakly on the bed, he asked her the same question for the first time. She smiled and answered peacefully, "I did not miss having you in this life." The husband burst into tears and felt so sorry for never being thoughtful to his wife over the past 50 years.





The story gives the city dwellers a chance to reflect on our relationships with people around us, and the meaning of life. We are driven by self-interest, the pursuit of social or peer recognition, and other physical desires in most of our lifetime, but rarely do we realize the importance of love, family and friends, not until they are gone. As Mother Teresa said, "we have been created for greater things, not just to be a number in the world, not just to go for diplomas and degrees, this work and that work. We have been created in order to love and to be loved."

"May the Lord increase and enrich your love for each other and for all, so that it matches ours for you." (1Thessalonians 3:12). I believe that God created the world not because of co-incidental intentions but to reflect His love through a healing mission. We love our patients as much as God loves us. I am thankful that the healing mission of Jesus Christ is being carried out in St. Paul's Hospital through the tremendous support, strong commitment and unwavering dedication of our medical professionals and staff to the people in need. I'd like to express my deepest gratitude to you at the turn of a new year, and may you be filled with blessings and the love of God at all time.

Sr. Nancy Cheung





Vacuum-assisted Excision for Benign Breast Lesions

The vacuum-assisted breast biopsy (VABB) system was first developed in 1995.¹ It was initially designed as a diagnostic tool to obtain a sufficient amount of breast specimen to provide a more accurate diagnosis compared with conventional core biopsy.

In 2002, the Food and Drug Administration approved the use of the VABB system for the therapeutic purpose of benign lesions,² as could provide complete removal of lesions under real-time ultrasonic guidance. Many studies have evaluated the use of the VABB system, and the authors of those studies have concluded that using the VABB system in resecting breast fibroadenoma with a small incision is feasible and safe, and yields a high patient satisfaction rate of up to 97 per cent. It can be performed under local anaesthesia in outpatient settings. The complete removal of breast fibroadenoma using the VABB system was found to have only minimal complications. Lesions up to 2.5-3 cm can be completely removed with minimal or no scarring.3 The use of an 8-gauge needle is recommended for nodules > 1 cm in size. During the procedure, lesions must be removed as completely as possible to prevent re-growth, and extra samples should be obtained in different directions to ensure complete removal.

Incomplete excision is attributed to the limitation of the use of the VABB system in the excision of benign breast lesions. Fine et al. reported that 97 per cent of women in their study demonstrated complete removal of the imaged mass immediately after biopsy.⁴ However, 27 per cent had a residual mass during a follow-up ultrasound 6 months later. They suggested several possibilities for this issue, which included the use of local anaesthesia, which might blur the operative field and contribute to a visual challenge when the mass became smaller during the procedure, bleeding during the procedure and that the mass was not completely removed and became enlarged over the ensuing months. Nevertheless, the rate of successful initial complete removal of a lesion varies widely,

from 22 to 100 per cent, although most studies report rates of 75–100 per cent. Follow-up rates without recurrence are 62–98 per cent. These variations might be explained by the use of different gauge devices and different methods for assessing the completeness of removal, including clinical, radiological and histological assessments.





The reported complication rate of this procedure ranges 0 to 9 per cent, with a mean of 2.5 cent.

Haematoma is the most frequent post-procedure complication; others include subcutaneous bleeding, skin defects and pneumothorax. Most complications are of mild-to-moderate severity. Careful ultrasonic monitoring throughout the whole procedure is mandatory to avoid skin tear. Usually, subcutaneous bleeding can be controlled by direct compression, and crepe bandage for 24 h is recommended to diminish bruising.

In conclusion, the vacuum assisted excision of breast lesions using the VABB system is a feasible and safe procedure. Careful real-time ultrasonic monitoring is mandatory to avoid complications.

Reference

- 1. Parker SH, Dennis MA, Stavros AT, Jahnson KK. Ultrasoundguided mamtmeotomy: a new breast biopsy technique. J. Fiagn. Med. Sonogr. 1996; 12:
- Johnson AT, Henry-Tillman RS, Smith LF et al. Percutaneous excisional breast biopsy. Am. J. Surg. 2002; 184: 550-4.
- Tagaya N, Nakagawa A, Ishikawa Y, Oyama T, Kubota K. Experience with ultrasonographically guided vacuumassisted resection of benign breast tumors. Clin. Radiol. 2008; 63: 396-400.
- 4. Fine RE, Boyd BA, Whitworth PW, Kim JA, Harness JK, Burak WE. Percutaneous removal of benign breast masses using a vacuum-assisted hand-held device with ultrasound guidance. Am. J. Surg. 2002; 184: 332-6.



Based on the elimination half-life of 6-8 hours, one would argue that Levofloxacin is best dosed twice daily. However, the usual recommended doses are given with a twofold potency to allow for once-daily dosing as guinolones exhibit concentration-dependent killing and post-antibiotic effects, similar to that of aminoglycosides.¹ If pharmacodynamic modeling is not convincing enough for our prescribers, the IMPACT guidelines will hopefully persuade you from a different

perspective. According to the fourth edition published in 2012, it specifically mentions that the use of Levofloxacin less than 500mg in divided doses should be avoided as it has been associated with increased resistance to the fluoroguinolone family by S. pneumonia.2 With the benefit of Levofloxacin oncedaily dosing, our prescribers can surely be the spearheads to promote better patient compliance and to limit the emerging fluoroquinolone-resistance.

Reference

- 1. Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998; 279:125.
- 2. Ho, P.L., and Wong, S.Y, eds. Reducing bacterial resistance with IMPACT. 4th ed. 2012. Print.

New Drugs Available at St. Paul's Hospital

Following DTC's decision in October, the following drugs are now approved to be used in St.Paul's Hospital

Edarbi (azilsartan) tablet - This is a new angiotensin II receptor blocker (ARB) for the treatment of essential hypertension. The usual dosage is 40-80mg daily, lower dosage 20mg can be used as starting dose for patients age ≥ 75years. Edarbi can be used in patients with mild or moderate renal impairment without dosage adjustment. For patients with hepatic impairment, close monitoring is required with mild to moderate hepatic impairment and a lower starting dose of 20mg.

Phoxilium 1.2mmol/L phosphate solution - This is a solution for haemodialysis or haemofiltration. Compare to Hemosol B0, Phoxilium contains 1.2mmol/L of phosphate after reconstitution. Such addition of phosphate can prevent hypophosphataemia during therapy. It also contains a small amount of potassium (4mmol/L).

Tiotropium Resipmat inhaler - This is a new formulation of tiotropium inhaler and allows the delivery of tiotropium in the form of soft mist. It is especially useful in patients who have poor dexterity and cannot handle the HandiHaler. Patients should inhale 2 puffs (5mg) once daily from Tiotropium Resipmat inhaler. Resipmat and HandiHaler have similar efficacy and safety profile. In terms of cost, the new Resipmat inhaler is about 30% higher than the original Handihaler.

Onbrez (Indacaterol) Breezhaler - This is a long acting beta2-adrenergic agonist, indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD). The recommended dose is 150mg capsule once daily and can be increased to 300mg capsule daily. The use of Onbrez has

shown to improve the breathlessness especially in patients with severe COPD. Onbrez Breezhaler is not indicated in asthma due to the lack of long term outcome data in this group of patients. Long-acting beta2-adrenergic agonists may increase the risk of asthma-related serious adverse events, including asthma-related deaths, when used for the treatment of asthma.

(oxycodone) injection and tablet Oxynorm (Dangerous Drug) - Oxynorm is an µ-opioid receptor agonist but it has a lower μ -opioid receptor binding affinity than morphine. It is indicated for the treatment of moderate to severe pain, and currently it is mainly used in postoperative pain management at SPH. Oxynorm injection can be administered as IV bolus (dilute to 1mg/ml in NS 0.9% or water for injection, at 1 to 10mg slowly over 1 to 2 minutes every 4 hours), IV infusion (dilute to 1mg/ml in NS 0.9% or D5W, at the starting dose of 2mg/hour), IV PCA (dilute to 1mg/ml in NS 0.9% or D5W, with bolus dose of 0.3mg/kg and lockout time of 5 minutes), subcutaneous injection (undiluted, with a starting dose of 5mg every 4 hours). Oxynorm capsule is given every 4 to 6 hours, with starting dose of 5mg in opioid naïve patients. The dose can be increased according to the patient's response. When switching patients between Oxynorm capsule and injection, the dose should be based on the ratio 2:1 (oral: parenteral). It must be emphasized that this is a guide to the dose required. Inter-patient variability requires that each patient is carefully titrated to the appropriate dose. Oxynorm has a similar safety profile to other opioids such as morphine. Common adverse effects include anorexia, dizziness, sedation, constipation, nausea/vomiting, dry month, rash.

St Paul's Hospital (Clinical Microbiology)

Antibiogram of Bacteria Isolated in 2013^a

Organisms (no. of isolates)	Ampicillin	Amoxycillin/clav	Cloxacilin	Piperacillin/tazo	Cefuroxime	Ceftazidime	Ceftriaxone	Cefepime	Amikacin	Gentamicin	Netilmicin	Ciprofloxacin	Levofloxacin	Ertapenem	Imipenem	Meropenem	Azithromycin	Clarithromycin	Clindamycin	Co-trimoxazole	Nitrofurantoin	Linezolid	Vancomycin
Enterococcus species (117)	2									53		21										0	0
Escherichia coli (805)	72	38			27		25	25	5	33			34	0		0				47	5		
Haemophilus influenzae (23)	43	22			13			0					0				0			71			
Klebsiella pneumoniae (186)	100	31			24		21	22	2	11			20	0		0				37	55		
Proteus mirabilis (54)	37	17			15		9	9	0	6			31	0		0				31	100		
Pseudomonas aeruginosa (137)		5		7		8		7		9		19	21		20								
Staphylococcus aureus (341)		29	29		29												40	40	36	0		0	0
Stenotrophomonas maltophilia (35)													21							0			
Salmonella species (63)	43										0	35								13			

Interpreted according to CLSI
 (Clinical & Laboratory Standards Institute)

Indicated 10% more increase in resistant rate compared to 2012 figures

Indicated 10% more reduction in resistant rate compared to 2012 figures



檢查服務,包括血壓量度、上下肢血壓比、足部健康檢 查、乙型肝炎抗原快速測試、膽固醇及血糖測試、心電 圖檢查、口腔檢查、骨質密度測試、眼科白內障檢查以 及腹部(肝膽)、婦女盤腔(子宮內膜厚度)、腹腔大動脈 及頸動脈(血管壁內層厚度)等超聲波掃描檢查。當日, 除了提供各項健康檢查服務外,活動更設有由牙科診所 及內視鏡中心負責的攤位遊戲,與眾同樂。同時本院亦 開放轄下的心臟中心、內視鏡中心及磁力共振中心予大 眾參觀。是次活動能順利舉行,全賴本院合共約五十名 醫護人員、修女、醫生及義工的熱心參與和支持。



修女及義工為參加者 提供不同類型的健康檢查。











修女及義工為市民量度血壓、骨質密度及血液測試。

油尖旺區外展健康檢查日

(27/10/2013)

<mark>聖保祿醫院於二</mark>零一三年十月二十七日與旺 角街坊會陳慶服務中心、沙田婦女會及旺角 金域扶輪社合辦外展活動。當日,本院合共 五十名熱心的醫護人員、修女、醫生及義工 全力參與支持此活動。除替超過二百名旺角 區街坊和長者量度血壓及骨質密度測試外, 義工亦替百多名市民提供血液檢驗,包括膽 固醇及血糖測試。另有數十名市民接受腹部 及頸動脈超聲波檢查。









沙爾德聖保祿女修會何美蘭省會長及執行董事張柱 見修女頒發十年、二十年及三十年長期服務獎予有 關員工。



二零一三年

聖保祿醫院聖誕聯歡晚宴

(10-11/12/2013)

「二零一三年聖保祿醫院聖<mark>誕聯歡晚宴」於二零一三年十二月</mark> 十日及十一日一連兩晚假銅鑼灣富豪酒店舉行。是次聯歡晚宴 共延開八十席,有近千名來賓出席,包括神父、修女、醫生、 職員及本院的合作伙伴。晚宴亦有頒發長期服務獎予服務了十

年、二十年及三十年的同事,以表揚他們多年來為本院作出的貢獻。在表演節目方面,,更聯同復康中心的劉業光醫生除了表演色士風外,更聯同復康中心、人力資源部和診斷及介的財部之同事一起為來實演奏耳熟能詳的歌曲。他們的精彩表演充分發揮了團隊的有擊,將晚宴氣氛推至頂峰。本院更有高歌一時,將晚宴氣氛推至頂峰。本院更有高歌一時,將晚宴氣氛推至頂峰。本院更有高歌一時,將晚宴氣氛推至頂峰。本院更有高歌一時,將晚宴氣氛推至頂峰。本院更有高歌一時,將晚宴氣氛推至頂峰。本院更有高歌一時,將晚宴氣氛推至頂峰。本院更有為時,將晚宴氣氛推至頂峰。本院更有為時,以表述。



































週年火警演習

(03/12/2013)

保障病人及員工的安全是聖保祿醫院一向堅守的承 諾。為確保醫院一旦發生火警時,對病人及員工的 影響減至最低,本院於二零一三年十二月三日舉行 了週年大型火警演習,模擬A18病房之醫療儀器失 火,以測試有關部門的應變反應。參與是次大型火 警演習的員工及模擬病人來自醫院各個部門, 人數 多達三百多名。香港消防處亦派出一隊消防人員到 本院觀察整個演習過程。

指揮中心成員在火警中擔當重要的

統籌及溝通工作。

演習的結果理想,參與的臨床醫護人 員及後勤支援部門員工,均能在事發 時按照既定機制執行有關的應變措 施,並能有秩序地進行 疏散。分享會 於演習後進行,本院感謝消防人員在 場為我們提供寶貴意見,以進一步完 善及優化本院的火警應變措施。





火警訊息。



屏山盆菜宴 體驗圍村情

(08/02/2014)

圍村盆菜宴是鄧氏村民於農曆新年的一大盛事。 今年,何醫生、袁醫生與骨科及復康中心一眾同 事被邀請參與,與過百嘉賓同渡新春。

2013年追思彌撒

(13/11/2013)

人生變幻無常,對於我們日夕照 顧和相處的病人及擊愛的親友的 離世,我們都感到唏嘘和懷念不 已。聖保祿醫院每年一度的追思 彌撒,正給予我們一個懷緬亡 者,為他們的安息而祈禱的機 會。

 上,場面莊嚴而肅穆。全體參禮 者在周景勳神父的帶領下,為亡 者作深切的祈禱和鞠躬敬禮,以 表示對他們的思念。

雖然追思彌撒己完結,家屬、職員及參禮者各人將繼續為亡者祈禱,希望他們能早登天國,獲享永恆福樂。儀式能順利舉行,全賴禮儀工作人員的努力合作。我們也感激醫院各部門派員工代表出席。願主福佑各位!

牧靈部







年終謝主感恩聖祭後記

(21/01/2014)

你們「不要為生命思慮吃什 麼,也不要為身體思慮穿什 麼,因為生命貴於食物,身 體貴於衣服。」福音中提醒 我們不要為身外物而營營役 役或過於掛慮,卻忘記了那 永恆及有真正價值的事物。 甘神父提及,中國傳統的除 夕歲晚團圓也引伸為我們在 日常生活及工作中的團結、 共融。適逢是基督徒合 週,他又鼓勵我們在醫院 工作間,不管是教友、非教 友、朋友或家人,都需要團 結一致。我們在不同的崗位 承擔著不同的責任,只有互

相包容和扶持,工作才可 暢快及順利。

牧靈部



INTRODUCTION

OF NEW FACES



Dr. Tsang Yee Yan, Yvonne Specialist in General Surgery

Dr. Tsang Yee Yan, Yvonne is currently a Specialist in General Surgery in St. Paul's Hospital. Prior to the current appointment, she was the associate consultant and in charge of breast service in the Department of Surgery, Pamela Youde Nethersole Eastern Hospital. She is also honorary clinical assistant professor of University of Hong Kong and The Chinese University of Hong Kong.

Yvonne graduated from The Chinese University of Hong Kong and received her surgical training in the Prince of Wales Hospital and North District Hospital. She

also obtained overseas training in Nottingham Breast Institute and Seoul National University Hospital where she specialized in Oncoplastic Surgery. Her special interests include Oncoplastic Surgery for breast cancer patients and Minimal Access Surgery, vacuum-assisted excision for benign breast diseases. She also participates in Breast Cancer Registry in St Paul's Hospital in collaboration with Hong Kong Breast Cancer Foundation. Yvonne is also currently the vice chairlady of Women's Chapter of The College of Surgeons of Hong Kong.



Personal Contact Details Update

To ensure you receive important updates from St. Paul's Hospital, please complete and return the following form to us (Email: vmo@stpaul.org.hk; Fax: 2837 5241) if you have updated or changed any of your previous information. Information collected will be used for Hospital communications only. Please note that it takes about ten working days to update your contact information in our system.

Personal Particulars		
Name of Physician: (IN	FULL NAME)	
English:	Chinese:	Physician Code:
Correspondence (Plea	se write down changed items only)	
Address:		
Phone:	Pager:	Mobile:
Fax:	Email:	Effective Date:
Others:		
Signature:		
Please return the completed	form by	
1) Fax: 2837 5241 2) E	Email: vmo@stpaul.org.hk	
3) Post: 2 Eastern Hospital	Road, Causeway Bay, Hong Kong (Attn: Hospita	al Management Department)
•	Thank vou!	